Shinichiro Watanabe's Lazarus took Best Original Anime at the 10th Crunchyroll Anime Awards on May 23, 2026, in Tokyo — and for viewers who paid attention to the science, the win feels like an award going to a show that did something most biotech thrillers don't: it anchored its central catastrophe to a real gene, a real pharmaceutical puzzle, and a real public health failure that killed several of Watanabe's favorite musicians.
The fictional drug Hapna, which in the show silences all pain and then kills its users after roughly three years, is not a generic sci-fi MacGuffin. A later episode, "Pretty Vacant," narrows the mechanism to a single gene: SCN9A, which encodes the Nav1.7 voltage-gated sodium channel in dorsal root ganglion neurons. That is a real gene that real pharmaceutical companies have been trying — and repeatedly failing — to exploit for over a decade.
The full list of 2026 Crunchyroll Anime Awards winners confirms Lazarus beat out nominees including Apocalypse Hotel, Digimon Beatbreak, Gundam GQuuuuuuX, Moonrise, and ZENSHU. The ceremony at the Grand Prince Hotel Shin Takanawa drew a record 73 million fan votes globally. Watanabe did not attend; producers Joseph Chou and Masato Matsunaga accepted the award on his behalf. "I was very surprised that out of a lot of amazing elite shows, Lazarus was given the honor of winning," Chou said from the stage. The win was, by multiple accounts, an upset: Lazarus did not air on Crunchyroll in North America during its original run, broadcasting instead on Adult Swim's Toonami block and streaming on Max the following day.
What Is the SCN9A Gene and Why Does Hapna Target It?
The SCN9A gene encodes a protein called Nav1.7, a voltage-gated sodium channel that sits in the membranes of nociceptive neurons — the cells that detect and transmit pain. People who carry rare loss-of-function mutations in SCN9A are born with congenital insensitivity to pain: they feel no pain at all from birth, with no apparent cognitive or motor impairment.
The science behind the show's Dr. Skinner is visible in this detail: the character is explicitly shown studying populations with congenital analgesia — the human natural experiment that made Nav1.7 one of the most aggressively pursued analgesic targets in pharmaceutical history. If you could block that channel the way nature already does in those patients, the argument goes, you would have a pain drug with almost no side effects. The show extrapolates from a real biological proof-of-concept.
Lazarus ran for 13 episodes on Adult Swim from April 6 to June 29, 2025, directed by Watanabe and animated by MAPPA, with action sequences designed by Chad Stahelski of the John Wick franchise and a score composed by jazz saxophonist Kamasi Washington alongside electronic artists Bonobo and Floating Points.
Nav1.7 Pain Research Keeps Failing in Clinical Trials
Here is where the show's science fiction outpaces the science: pharmaceutical companies have been developing selective Nav1.7 inhibitors for years and they keep failing in clinical trials — not because the preclinical data is wrong, but because something else is happening in human patients that rodent studies did not predict.
A 2025 study published in the journal Pain reviewed preclinical and clinical reports on Nav1.7-selective inhibitors and found the gap troubling: most preclinical studies tested young male rodents with limited genetic variability, while clinical trials focused on neuropathic pain, where Nav1.7 may play a different role than rodent inflammatory pain models suggested.
The deeper reason emerged from a landmark 2015 Nature Communications study by Minett and colleagues. When Nav1.7 is deleted in mice — replicating what happens naturally in humans with congenital analgesia — the nervous system does not simply go quiet: it floods itself with endogenous opioids. Specifically, Nav1.7 deletion causes a massive upregulation of enkephalin precursor Penk mRNA and met-enkephalin protein in sensory neurons. The opioid antagonist naloxone dramatically reverses analgesia in both Nav1.7-null mice and a human Nav1.7-null patient, confirming that the pain-free state depends substantially on internally produced morphine-like molecules, not only on channel silence.
This means a drug that simply blocks the Nav1.7 channel may not replicate what genetic deletion achieves — because the deletion also, paradoxically, induces the endogenous opioid flood that may be doing most of the analgesic work. Watanabe's Hapna, which produces a "utopian peace" across a medicated global population, accidentally dramatizes this: a world silenced by Nav1.7 suppression could plausibly be a world running on internally produced opioids it doesn't know it has.
The active pharmaceutical pipeline has moved in response. Patent analysis shows Nav1.7 indirect approaches — specifically CRMP2 peptide-mediated trafficking interference and enkephalinase-based co-administration — are being developed as potentially superior to direct channel blockade, with multiple companies and academic groups filing across jurisdictions.
Watanabe Built Hapna From Real Opioid-Crisis Logic
In multiple interviews before and after the show's premiere, Watanabe was clear that the inspiration for Hapna was not allegory. "The biggest inspiration on Lazarus was the opioid crisis that's currently going on," he told JoySauce. "And a lot of my favorite musicians have passed away because of it — I was shocked when Prince passed away due to opioids as well."
In his Deadline interview, Watanabe described the mechanism more precisely: "I thought that maybe you could make a drug that would be similar in the way that it would be like an opioid but also designed to kill people in a certain amount of years. Whenever I talk about this, people ask if this is a metaphor for the opioid crisis, but it is not really like that."
The structural parallel he was constructing mirrors how OxyContin was marketed in the 1990s: presented as having an addiction rate below one percent, it created medical dependency before that claim collapsed under documented evidence. Hapna is legally prescribed, has no apparent side effects at first, creates global dependency, and is then revealed to kill. The logical extension Watanabe identified was not invented — it was one step further down a path real pharmaceutical companies had already taken.
How Does Hapna Actually Work, and Where Does the Science Break?
The show's science holds up well through its first claim — that Nav1.7 loss-of-function produces complete analgesia — and begins to strain at the edges. Peer-reviewed research confirms that ASIC3, TRPV1, and Nav1.8 each play distinct roles in pain perception, operating through different mechanisms in heat, mechanical, and chemical pain pathways. A drug targeting only SCN9A/Nav1.7 would leave those other channels untouched, meaning it would likely be an incomplete analgesic at best.
A realistic Hapna would almost certainly require a drug cocktail or a gene-editing approach rather than a single small-molecule intervention. The show acknowledges this implicitly by making Hapna's mechanism a black box — Skinner's genius is treated as narrative grant, not demonstrated science.
Where the latent-kill mechanism is concerned, the show is wisely vague. Programming a molecule to become lethal after exactly three years across a genetically diverse global population would require either a specific metabolic cascade, an epigenetic timer, or a mechanism embedded in the gene edit itself. None of those approaches exist. Prodrug chemistry and epigenetic timers are active research areas, but the precision required for a synchronized three-year kill window defeats current biology. The show's choice to leave this mechanism unexplained is the correct one: it is the MacGuffin that drives the plot, not the scientific claim that earns scrutiny.
What the Crunchyroll Win Signals About Hard-Sci-Fi Anime
Lazarus competed against titles with large existing fanbases: Apocalypse Hotel, Digimon Beatbreak, Gundam GQuuuuuuX, Moonrise, and ZENSHU. Its community score on Rotten Tomatoes sits at 60 percent against a 92 percent critical consensus — a gap indicating the show was ahead of casual viewers but validated by reviewers and more engaged audiences. The Crunchyroll win, for a show that never aired on Crunchyroll in North America, suggests that global anime audiences will reward original, scientifically literate IP when it delivers on production quality.
Watanabe himself seemed satisfied with what the show accomplished under its production conditions. "Personally, I think I did my best within the given conditions and created a great work," he said in a 2025 interview. A Season 2 has not been announced.
The broader commissioning signal for streaming platforms is legible: Lazarus navigated a near-cancellation — initially developed for HBO Max before Adult Swim salvaged it — and still became the most-awarded original anime of the year. For decision-makers at platforms considering science-grounded original anime IP through 2027 and 2028, that is a data point worth noting.
Frequently Asked Questions
What is the Lazarus anime about?
Lazarus is a 13-episode science fiction anime set in 2052, directed by Shinichiro Watanabe and animated by MAPPA. A neuroscientist named Dr. Skinner develops Hapna, a drug that eliminates all pain and appears to have no side effects, before disappearing. Three years later he resurfaces to announce the drug carries a lethal three-year expiration — and a task force is assembled to find him before the global population dies.
Is the science in Lazarus real?
Partially. The show's central mechanism targets SCN9A, the real gene encoding the Nav1.7 sodium channel, which plays a documented role in human pain perception. People with congenital loss-of-function mutations in this gene genuinely feel no pain from birth, making it a real pharmaceutical target. The show invents the latent-kill mechanism and the single-drug simplicity, both of which exceed current biology — and real Nav1.7 drugs have repeatedly failed in clinical trials for reasons the show does not address.
Where can I watch the Lazarus anime?
Lazarus aired on Adult Swim's Toonami block in the United States from April 6 to June 29, 2025, and streamed on Max the day after each broadcast premiere. The series is confirmed to re-air on Toonami later in 2026. In Japan it aired on TV Tokyo and its affiliates.
Why do Nav1.7 pain drugs keep failing in clinical trials?
Nav1.7 inhibitors have shown strong analgesic results in rodent studies but consistently underperform in human trials. A leading explanation, identified in a 2015 Nature Communications study, is that deleting Nav1.7 in mice triggers a large increase in endogenous opioid production — meaning the pain relief comes partly from internally produced morphine-like molecules, not just channel blockade. A drug that blocks the channel without triggering that opioid response may therefore fail to replicate what genetic deletion achieves.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
